⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 18, 2026Pulmonary Pharmacology & Therapeutics

Posaconazole attenuates arsenic trioxide toxicity and enhances safety and efficacy while reducing invasion and metastasis in non-small-cell lung cancer

Shima Karami Azra Rabbani-Chadegani Jamshid Davoodi

View at Publisher

Ask AI

Bookmark

Share

Key Points

Posaconazole significantly reduces arsenic trioxide toxicity, enhancing overall treatment safety.
The study found that posaconazole decreased invasion and metastasis, promoting better control over cancer progression.
Analysis demonstrated improved treatment efficacy, leading to favorable outcomes in non-small-cell lung cancer models.
Combining posaconazole with arsenic trioxide may provide a new strategy, emphasizing the need for clinical trials.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Observational analysis shows posaconazole enhances safety and efficacy in non-small-cell lung cancer, suggesting it may improve treatment outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Karami et al. (2026) studied this question.

synapsesocial.com/papers/69a761b7c6e9836116a2fc4e https://doi.org/10.1016/j.pupt.2026.102412

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The metastasizing mechanisms of lung cancer: Recent advances and therapeutic challengesReview · 2021 · 198 citations
2Gli1 promotes epithelial–mesenchymal transition and metastasis of non-small cell lung carcinoma by regulating snail transcriptional activity and stabilityOriginal Research · 2022 · 99 citations
3Artificial Intelligence-Driven Innovations in Oncology Drug Discovery: Transforming Traditional Pipelines and Enhancing Drug Design2025 · 35 citations
4Emerging Applications of Triazole Antifungal DrugsReview · 2026 · 5 citations
5The Clinically Approved Antifungal Drug Posaconazole Inhibits Human Cytomegalovirus ReplicationOriginal Research · 2020 · 37 citations

More related papers

Possibility of re-purposing antifungal drugs posaconazole & isavuconazole against promastigote form of Leishmania major2024
Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic2016
Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells2018

More from Pulmonary Pharmacology & Therapeutics

Effects of anumigilimab, an anti–G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteersMon,
The importance of biomarkers in the treatable-trait approach to chronic airway diseasesMon,